A Study to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma Intravenously (IV) Infused ABBV-383 or Receiving Standard Available Therapies

Conditions: Multiple Myeloma Interventions: Drug: ABBV-383; Drug: Carfilzomib; Drug: Pomalidomide; Drug: Elotuzumab; Drug: Selinexor; Drug: Bortezomib; Drug: Dexamethasone Sponsors: AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials